Search results for "Tag"

showing 10 items of 10735 documents

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cance…

2021

Background: The addition of PD-L1 inhibitors to platinum-based chemotherapy (CT) has newly received United States Food and Drug Administration (FDA) approval in extensive stage-small cell lung cancer (ES-SCLC). PD-1 agents similarly improved survival rates, even if not yet supported by international regulatory agencies. The current work aims to assess different efficacy and safety profiles among chemoimmunotherapy plus immuno-oncology (CT+IO) approaches according to different immune checkpoint inhibitor (ICI) subtypes. Material & Methods: We included in our meta-analysis six first-line randomised controlled trials (RCTs) comparing the association of single-agent ICI with CT versus CT al…

0301 basic medicineOncologymedicine.medical_specialtyImmunotherapy for Lung Cancer: Progress Opportunities and Challengesmedicine.medical_treatmentCellFood and drug administration03 medical and health sciences0302 clinical medicineInternal medicinemedicinechemo-immunotherapy ES-SCLC indirect comparison meta-analysis PD-L1/PD-1 inhibitorsChemo immunotherapyRC254-282ChemotherapyLungbusiness.industryPD-L1/PD-1 inhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensIndirect comparison030104 developmental biologymedicine.anatomical_structureOncologyindirect comparison030220 oncology & carcinogenesisMeta-analysischemo-immunotherapybusinessExtensive-stage small cell lung cancerES-SCLCMeta-AnalysisTherapeutic Advances in Medical Oncology
researchProduct

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab …

2018

Objective In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease. Methods Patients with stage IIB–IV or high-risk (grade 3/clear-cell) stage I–IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5 mg/kg every 3 weeks followed by single-agent bevacizumab for 12 further cycles (total duration 12 months). Post hoc ex…

0301 basic medicineOncologymedicine.medical_specialtyNeoplasm ResidualPaclitaxelBevacizumabmedicine.medical_treatmentPopulationArticleCarboplatin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansCytoreductive surgeryStage (cooking)educationNeoplasm StagingOvarian NeoplasmsChemotherapyeducation.field_of_studybusiness.industryHazard ratioObstetrics and GynecologyResidual diseasemedicine.diseaseCarboplatinBevacizumab030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemaleOvarian cancerbusinessmedicine.drug:Ciencias de la Salud::Oncología [Materias Investigacion]
researchProduct

Liquid Biopsy in Breast Cancer

2017

Breast cancer (BC) to date remains the most common cancer in women. Nowadays, BC is often diagnosed at local disease stage, and, after surgery, based on individual’s risk of relapse, the patients undergo adjuvant systemic treatment to decrease the risk of recurrence. Current BC classification and assessment remain strongly based on clinicopathological criteria, including patient age, tumor size, lymph node invasion, histological type, and grade. According to standard practice, the choice of treatment strategy includes assays for estrogen (ER) and progesterone (PgR) receptor expression levels, overexpression of human epidermal growth factor receptor 2 (Her-2), or amplification status of the …

0301 basic medicineOncologymedicine.medical_specialtyOncogenebusiness.industryReceptor expressionCancerDiseasemedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureBreast cancer030220 oncology & carcinogenesisInternal medicinemedicineLiquid biopsyStage (cooking)businessLiquid Biopsy Breast CancerLymph node
researchProduct

CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients und…

2016

AbstractObjective: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes.Patients and methods: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count.Results: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival.Conclusions: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients…

0301 basic medicineOncologymedicine.medical_specialtyPathologyChemokineLung NeoplasmsAngiogenesisHealth Toxicology and MutagenesisClinical Biochemistrynon-small cell lung cancer (NSCLC)Platelet Factor 4BiochemistryDisease-Free Survival03 medical and health sciences0302 clinical medicineVascularityInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansStage (cooking)biologyNeovascularization Pathologicbusiness.industryLigand (biochemistry)medicine.disease030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisbiology.proteinImmunohistochemistrymedicine.symptomNeoplasm Recurrence LocalbusinessPlatelet factor 4BiomarkersBiomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
researchProduct

Is immunohistochemical evaluation of p16 in oropharyngeal cancer enough to predict the HPV positivity?

2016

Abstract Aim Our goal was to determine the expression levels of p16 in the cohort of the OPSCC patients and evaluation of the pathological and clinical differences between these two groups including patients’ survival. Background HPV infection is the main causative factor of oropharyngeal cancer (OPSCC). Identification of HPV status in OPSCC requires positive evaluation of viral DNA integration into host cell however, p16 accumulation in the proliferating cell layers has been accepted as an alternative marker for HPV infection. Material and Methods The IHC staining for p16 has been performed in tumor tissue from 382 OPSCC patients. The sample was considered positive based on more than 70% o…

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryHPV infectionCancermedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineCohortmedicineCarcinomaImmunohistochemistryRadiology Nuclear Medicine and imagingOriginal Research ArticleStage (cooking)businessPathologicalImmunostainingReports of Practical Oncology and Radiotherapy
researchProduct

Mid-region parathyroid hormone-related protein is a genome-wide chromatin-binding factor that promotes growth and differentiation of HB2 epithelial c…

2018

Human parathyroid hormone-related protein (PTHrP) is a polyhormone that undergoes proteolytic cleavage producing smaller peptides which exert diversified biological effects. PTHrP signalization is prominently involved in breast development and physiology, but the studies have been focused onto either N-terminal species or full-length protein introduced by gene transfer techniques. Our present work investigates for the first time the effect of the mid-region PTHrP secretory form, that is, the fragment [38-94], on HB2 non-tumoral breast epithelial cells. We examined viability/proliferation of cells grown in PTHrP-containing media supplemented with different serum concentration and on differen…

0301 basic medicinePTHrPCellClinical BiochemistryBiochemistryCell Line03 medical and health sciences0302 clinical medicineCell Line TumorGene expressionmedicineHumanscell growthBinding siteSettore BIO/06 - Anatomia Comparata E CitologiaCell ProliferationParathyroid hormone-related proteinChemistryCell growthChromatin bindingParathyroid Hormone-Related ProteinCell DifferentiationEpithelial CellsGeneral MedicineChromatinCell biologychromosome decorationSettore BIO/18 - Genetica030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbreast cellgene expressionMolecular MedicineFemaleReprogramminghormones hormone substitutes and hormone antagonists
researchProduct

Recommendations for the introduction of metagenomic high-throughput sequencing in clinical virology, part I: Wet lab procedure

2020

Metagenomic high-throughput sequencing (mHTS) is a hypothesis-free, universal pathogen detection technique for determination of the DNA/RNA sequences in a variety of sample types and infectious syndromes. mHTS is still in its early stages of translating into clinical application. To support the development, implementation and standardization of mHTS procedures for virus diagnostics, the European Society for Clinical Virology (ESCV) Network on Next-Generation Sequencing (ENNGS) has been established. The aim of ENNGS is to bring together professionals involved in mHTS for viral diagnostics to share methodologies and experiences, and to develop application recommendations. This manuscript aims…

0301 basic medicinePathogen detectionStandardizationComputer science030106 microbiologyRecommendationsINFLUENZA-A VIRUSDIAGNOSISVALIDATIONDNA sequencing03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingVirologyWet labViral metagenomics030212 general & internal medicine11832 Microbiology and virologyLaboratory methodsHigh-throughput sequencingQuality assessmentNetwork onHigh-Throughput Nucleotide SequencingDNAEFFICIENT TRANSLATIONData science3. Good healthInfectious DiseasesMetagenomicsVirusesNext-generation sequencing3111 BiomedicineMetagenomicsDEPLETIONMESSENGER-RNAClinical virologyPATHOGEN DETECTIONJournal of Clinical Virology
researchProduct

Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence

2016

Bladder cancer has an unexplained, high recurrence rate. Causes of recurrence might include the presence of sporadic tumor micro-foci in the residual urothelial tissue after surgery associated with an inverted ratio between intratumoral effector and regulatory T cell subsets. Hence, surgical specimens of both tumors and autologous, macroscopically/histologically free-of-tumor tissues were collected from 28 and 20 patients affected by bladder or renal cancer, respectively. The frequencies of effector (IFNγ+ and IL17+ T cells) and regulatory (CD4+CD25hiCD127lo and CD8+CD28-CD127loCD39+ Treg) T cell subpopulations among tumor infiltrating lymphocytes were analyzed by immunofluorescence, while …

0301 basic medicinePathologyNeoplasm ResidualT-LymphocytesMessengerImmunoenzyme TechniqueFluorescent Antibody TechniqueCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryImmunoenzyme TechniquesTh10302 clinical medicineLymphocytesReverse Transcriptase Polymerase Chain ReactionResearch Paper: ImmunologyPrognosisRegulatoryBladder cancer; Immune response; Immunity; Immunology and microbiology section; Mage; Th1; Th17; Tumor infiltrating lymphocytes; CD8-Positive T-Lymphocytes; Case-Control Studies; Fluorescent Antibody Technique; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphocytes Tumor-Infiltrating; Melanoma-Specific Antigens; Neoplasm Grading; Neoplasm Proteins; Neoplasm Recurrence Local; Neoplasm Staging; Neoplasm Residual; Prognosis; RNA Messenger; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes Regulatory; Urinary Bladder Neoplasms; OncologyNeoplasm Proteinsmedicine.anatomical_structureLocalOncologytumor infiltrating lymphocytesResidual030220 oncology & carcinogenesisImmunology and Microbiology Sectionbladder cancerTh17Case-Control StudieMelanoma-Specific AntigenMelanoma-Specific AntigensHumanmedicine.medical_specialtyPrognosiRegulatory T cellT cellReal-Time Polymerase Chain ReactionMAGEFollow-Up StudieNeoplasm Protein03 medical and health sciencesLymphocytes Tumor-InfiltratingImmune systemAntigenmedicineHumansTumor-InfiltratingRNA MessengerImmune responseNeoplasm StagingBladder cancerTumor-infiltrating lymphocytesbusiness.industryImmunityCD8-Positive T-LymphocyteT lymphocytemedicine.diseaseNeoplasm Recurrence030104 developmental biologyUrinary Bladder NeoplasmsCase-Control StudiesNeoplasmRNANeoplasm GradingNeoplasm Recurrence Localtumor infiltrating lymphocytebusinessCD8Follow-Up StudiesOncotarget
researchProduct

Imaging in mice and men: Pathophysiological insights into multiple sclerosis from conventional and advanced MRI techniques

2019

Abstract Magnetic resonance imaging (MRI) is the most important tool for diagnosing multiple sclerosis (MS). However, MRI is still unable to precisely quantify the specific pathophysiological processes that underlie imaging findings in MS. Because autopsy and biopsy samples of MS patients are rare and biased towards a chronic burnt-out end or fulminant acute early stage, the only available methods to identify human disease pathology are to apply MRI techniques in combination with subsequent histopathological examination to small animal models of MS and to transfer these insights to MS patients. This review summarizes the existing combined imaging and histopathological studies performed in M…

0301 basic medicinePathologymedicine.medical_specialtyMultiple SclerosisNeuroimaging03 medical and health sciences0302 clinical medicineIn vivoBiopsymedicineAnimalsHumansStage (cooking)medicine.diagnostic_testbusiness.industryGeneral NeuroscienceMultiple sclerosisBrainMagnetic resonance imagingmedicine.diseaseMagnetic Resonance ImagingPathophysiology3. Good healthDisease Models AnimalEarly Diagnosis030104 developmental biologybusinessNeuroscience030217 neurology & neurosurgeryPreclinical imagingDiffusion MRIProgress in Neurobiology
researchProduct

2017

Recently, in vitro anti-cancer properties of beauvericin, a fungal metabolite were shown in various cancer cell lines. In this study, we assessed the specificity of this effect by comparing beauvericin cytotoxicity in malignant versus non-malignant cells. Moreover, we tested in vivo anticancer effects of beauvericin by treating BALB/c and CB-17/SCID mice bearing murine CT-26 or human KB-3-1-grafted tumors, respectively. Tumor size and weight were measured and histological sections were evaluated by Ki-67 and H/E staining as well as TdT-mediated-dUTP-nick-end (TUNEL) labeling. Beauvericin levels were determined in various tissues and body fluids by LC-MS/MS. In addition to a more pronounced …

0301 basic medicinePathologymedicine.medical_specialtyTUNEL assayColorectal cancerHealth Toxicology and MutagenesisPharmacologyBiologyToxicologymedicine.diseaseBeauvericinIn vitroStaining03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistryIn vivoApoptosis030220 oncology & carcinogenesismedicineCytotoxicityToxins
researchProduct